Evaluation of the potential for QTc prolongation with avelumab.
Saved in:
| Title: | Evaluation of the potential for QTc prolongation with avelumab. |
|---|---|
| Authors: | Vugmeyster Y; Clinical Pharmacology, EMD Serono Research and Development Institute, Inc, 45 Middlesex Turnpike, Billerica, MA, 01821, USA. yulia.vugmeyster@emdserono.com., Güzel G; Global Clinical Development Immuno-Oncology, Merck KGaA, Darmstadt, Germany., Hennessy M; Global Clinical Development, EMD Serono Research and Development Institute, Inc, Billerica, MA, USA., Loos AH; Global Biostatistics, Merck KGaA, Darmstadt, Germany., Dai H; Clinical Pharmacology, EMD Serono Research and Development Institute, Inc, 45 Middlesex Turnpike, Billerica, MA, 01821, USA. |
| Source: | Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2019 Nov; Vol. 84 (5), pp. 1017-1026. Date of Electronic Publication: 2019 Sep 03. |
| Publication Type: | Journal Article; Meta-Analysis |
| Journal Info: | Publisher: Springer Verlag Country of Publication: Germany NLM ID: 7806519 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0843 (Electronic) Linking ISSN: 03445704 NLM ISO Abbreviation: Cancer Chemother Pharmacol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1432-0843 |
|---|---|
| DOI: | 10.1007/s00280-019-03925-z |
